Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease

Gil-Candel, Mayte; Gascón-Cánovas, Juan José; Urbieta-Sanz, Elena; Rentero-Redondo, Lorena; Onteniente-Candela, María; Navalón, Carles Iniesta

doi:10.1007/s11096-020-00978-6

Cited by 15 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For psoriasis, the 12‐month drug survival of adalimumab and infliximab ranges from 75% to 84% and from 65% to 75%, respectively 13–15 . For inflammatory bowel disease, a higher survival rate at 12 months was also demonstrated for both adalimumab (estimated 65%) and infliximab (estimated 75%) 16 . In addition, Flouri et al .…”

Section: Discussionmentioning

confidence: 97%

“… 13 , 14 , 15 For inflammatory bowel disease, a higher survival rate at 12 months was also demonstrated for both adalimumab (estimated 65%) and infliximab (estimated 75%). 16 In addition, Flouri et al . showed a 1‐year estimated survival rate in spondyloarthritis of 85% for adalimumab and 90% for infliximab.…”

Section: Discussionmentioning

confidence: 99%

“…[13][14][15] For inflammatory bowel disease, a higher survival rate at 12 months was also demonstrated for both adalimumab (estimated 65%) and infliximab (estimated 75%). 16 In addition, Flouri et al showed a 1-year estimated survival rate in spondyloarthritis of 85% for adalimumab and 90% for infliximab. 17 The TNF-a-inteleukin-23-T helper cell 17 inflammatory pathways play a role in ankylosing spondylitis, Crohn disease and psoriasis, as well as in HS.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*

et al. 2021

View full text Add to dashboard Cite

B.H. reports fees from Janssen-Cilag (for advisory boards, educational grants, consultations, investigator initiative studies), AbbVie (for advisory boards, educational grants, consultations, investigator initiative studies), Novartis Pharma (for advisory boards, consultations, investigator initiative studies), UCB Pharma (for advisory boards, consultations), Leo Pharma (for consultations), Solenne B.V. (for investigator initiative studies), Celgene (for consultations and investigator initiative studies), Akari Therapeutics (for consultations and investigator initiative studies), Philips (for consultation), Roche (for consultation), Regeneron (for consultation) and Sanofi (for consultation); the fees were payed to the institution. E.P.P. has received honoraria from AbbVie, Amgen, Celgene, Janssen, Galderma, Novartis and Pfizer for participation as a speaker and for serving on advisory boards; E.P.P. also received investigator-initiated grants (paid to Erasmus MC) from AbbVie, AstraZeneca, Janssen and Pfizer.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Что касается группы получавших адалимумаб, из 14 анализируемых пациентов, рецидив заболевания отмечен у 2 (14%), причем одному (7,7%) В отношении вопросов безрецидивной выживаемости, стоит отметить, что наши данные подтверждают результаты исследования [12], в котором показано, что средний показатель лекарственной выживаемости составляет 20,2 месяца для адалимумаба и 17,1 месяца для инфликсимаба.…”

Section: результаты и обсуждениеunclassified

The effectiveness and safety of switching therapy with an original drug to biosimilars in treatment of inflammatory bowel diseases

Педа

Alexandrov

Baranova

et al. 2022

jour

View full text Add to dashboard Cite

Introduction. Inflammatory bowel diseases are a group of chronic, immune-mediated diseases of unknown etiology. Etiotropic therapy of IBD does not exist, all drugs used to treat IBD have a pathogenetic effect. In the treatment of IBD biologic therapy is used. The most previously registered group of biologics are anti-TNF-α. But, after the expiration of the relevant patents, biosimilars appeared on the market (analogs, comparable in quality to the already approved reference product).Materials and methods. A retrospective study was conducted on the basis of the Ryzhikh Natianal Medical Research Centre for Coloproctology of the Ministry of Health of the Russia, which included 46 patients who switched from therapy with the original inﬂiximab or adalimumab to biosimilar therapy.Discussion. This study showed that when switching therapy with the original drugs infliximab and adalimumab to biosimilars, the effectiveness of therapy does not significantly decrease with the use of biosimilars Infliximab BIOCAD and Dalibra. However, a statistically significant decrease in efficacy was revealed when switching from therapy with the original Infliximab to Flammegis. Considering that the use of biosimilars can reduce the cost of treatment and reduce the burden on the health budget, it is necessary to continue this study in order to obtain longer-term results.

show abstract

“…Geralmente, a escolha dos medicamentos ocorre por etapas (29) e podem incluir ácido aminosalicílico, corticosteroides, antibióticos, agentes imunossupressores e imunorreguladores, como os imunobiológicos (31)(32)(33). No entanto, pode haver efeitos colaterais significativos ou não responsividade pelos pacientes e, por essas razões, é importante identificar novas abordagens terapêuticas a fim de reduzir a inflamação crônica presente nestas doenças, sem prejudicar a resposta inflamatória fisiológica.…”

Section: Tratamentos Para Doenças Inflamatórias Intestinaisunclassified

Efeitos da melatonina no controle da colite experimental, via modulação da microbiota intestinal

Barbosa¹

View full text Add to dashboard Cite

Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease

Cited by 15 publications

References 27 publications

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*

The effectiveness and safety of switching therapy with an original drug to biosimilars in treatment of inflammatory bowel diseases

Efeitos da melatonina no controle da colite experimental, via modulação da microbiota intestinal

Contact Info

Product

Resources

About